Tadalafil dosage for erectile dysfunction is not a single number that applies to every patient. The U.S. Cialis label describes both an as-needed regimen taken in relation to anticipated sexual activity and a once-daily regimen taken on a regular schedule. These routes differ in tablet strengths, frequency and clinical assessment. The amount printed on a tablet does not tell a reader which schedule applies to their own prescription.
For as-needed ED treatment, U.S. labeling describes 10 mg as a usual starting strength for most patients, with adjustment to 5 mg or 20 mg based on response and tolerability. For once-daily ED treatment it describes 2.5 mg, potentially increased to 5 mg. These are population-level prescribing facts, not directions to begin, increase, divide or switch doses without a clinician.
This page explains the overall dosing framework rather than a tablet catalog. Compare the four labeled tablet strengths, review the individual daily and as-needed guides, or explore separate BPH-related indications. A valid prescription, the dispensing label and prescriber instructions control individual use.
The as-needed framework is linked to anticipated sexual activity. The U.S. label describes administration before sexual activity, generally no more than once per day in most patients, and a response window that may extend up to 36 hours. It does not support taking additional tablets simply because an erection has not happened immediately.
Once-daily tadalafil for ED uses lower labeled strengths at approximately the same time each day, regardless of when sexual activity occurs. Regular exposure creates different questions about missed tablets, interacting drugs and stopping treatment. Readers wanting practical differences should see daily versus as-needed tadalafil.
| U.S.-labeled ED framework | Label context | Editorial interpretation |
|---|---|---|
| As needed | 10 mg usual starting dose; may adjust to 5 mg or 20 mg | Prescriber evaluates response and tolerability; no extra self-directed doses |
| Once daily | 2.5 mg daily; may increase to 5 mg | Same-time routine, not event-by-event dosing |
| BPH or ED/BPH | Generally 5 mg once daily; the label also contains a 2.5 mg renal-adjusted starting exception | Diagnosis, creatinine clearance and other medicines can affect the prescribed plan |
The U.S. branded tadalafil ED product family includes tablets labeled 2.5 mg, 5 mg, 10 mg and 20 mg. These strengths are not a graduated menu to choose from by preference or an assurance that a larger number will produce a better outcome. Their roles depend on the prescribed indication and dosing schedule.
A pharmacy may dispense an FDA-approved generic with different tablet appearance and package identifiers. Patients should verify the prescribed strength and directions, not use tablet color or an online product photograph to infer how often to take the drug. The generic product guide explains the identity question.
For as-needed ED treatment, administration at least 30 minutes before anticipated sexual activity is described in counseling information. This is a planning instruction, not an onset guarantee; sexual stimulation remains necessary. Clinical studies evaluated erectile-function response at points as far as 36 hours after dosing.
Once-daily treatment is not anchored to an upcoming sexual encounter. Taking tablets on a prescribed regular schedule cannot be treated as permission to add an as-needed tablet, or to combine tadalafil with sildenafil or vardenafil. The focused administration guide discusses practical label-reading steps.
Renal function can materially change the permitted tadalafil dose and interval. In U.S. Cialis labeling, creatinine clearance (CrCl) 30–50 mL/min changes as-needed ED instructions to an initial 5 mg no more than once daily and a maximum 10 mg once every 48 hours; CrCl below 30 mL/min or hemodialysis limits as-needed use to 5 mg once every 72 hours. These are prescribing ceilings, not patient instructions to choose a dose. Once-daily tadalafil is not recommended when CrCl is below 30 mL/min or with hemodialysis.
For BPH or combined ED/BPH, the ordinary once-daily label lists 5 mg, but at CrCl 30–50 mL/min the recommended starting dose is 2.5 mg daily, with a possible clinician-directed change according to response. Mild or moderate hepatic impairment requires separate caution or adjustment depending on schedule; severe hepatic impairment is a setting in which Cialis is not recommended. A prescriber evaluates laboratory findings and the whole medication list rather than applying a public dosing table independently.
| Clinical circumstance | Relevant U.S.-label boundary | What readers should understand |
|---|---|---|
| As-needed ED, CrCl 30–50 mL/min | 5 mg starting context; maximum 10 mg once every 48 hours | Renal assessment changes the usual ED framework |
| As-needed ED, CrCl below 30 mL/min or dialysis | Maximum 5 mg once every 72 hours | A standard repeat interval is not appropriate |
| Once-daily ED/BPH, CrCl 30–50 mL/min | 2.5 mg starting context for BPH/ED+BPH; 5 mg may be considered | An exception to the usual BPH 5 mg starting framework |
| Once-daily tadalafil, CrCl below 30 mL/min or dialysis | Not recommended | Do not independently substitute a smaller daily tablet |
Nitrates, including nitroglycerin for angina, and soluble guanylate-cyclase stimulators such as riociguat are contraindicated with tadalafil. Other medicines can change its exposure. For patients taking potent CYP3A4 inhibitors such as ketoconazole or ritonavir, the Cialis label limits as-needed treatment to a maximum of 10 mg no more than once every 72 hours, while once-daily treatment must not exceed 2.5 mg. These are medication-specific prescribing limits, not suggested regimens.
Alpha-blockers and other blood-pressure medicines also need clinical review; using tadalafil with alpha-blockers for BPH is not recommended in the product labeling. Daily treatment produces ongoing exposure, making changes to other prescriptions important even when sex is not planned. Report prescription drugs, OTC products and supplements, and use the dedicated interaction guide for class-specific context.
Tadalafil has U.S. indications for erectile dysfunction, the signs and symptoms of benign prostatic hyperplasia, and patients with both. A low-strength tablet does not by itself identify which indication a clinician intended. BPH requires evaluation of urinary symptoms and potential alternative diagnoses.
The standard BPH/ED+BPH schedule is once-daily 5 mg, yet labeling includes a 2.5 mg starting exception when CrCl is 30–50 mL/min. In addition, using Cialis together with finasteride to initiate BPH treatment is recommended for up to 26 weeks, not automatically as an indefinite combination. See the indication-specific guide for symptom evaluation and the limits of the BPH evidence.
Prescribers may reassess effectiveness, adverse effects, cardiovascular status, concomitant drugs and whether the chosen schedule remains appropriate. Headache, flushing, indigestion, back or muscle pain can affect tolerability; persistent or troubling symptoms warrant professional discussion, not independent escalation.
An erection lasting more than four hours requires emergency care. Sudden vision or hearing loss requires stopping the medicine and prompt assessment. Chest pain during sexual activity is urgent; emergency clinicians need to know that tadalafil was taken so contraindicated drugs can be avoided.
A prescribed schedule affects tablet quantity and refill frequency, which may influence pharmacy billing. However, changing tablet strength, splitting tablets or adopting an unprescribed schedule merely for cost reasons can undermine treatment safety. The branded label instructs that Cialis tablets not be split.
For an evergreen explanation of ingredient, quantity, insurance and pharmacy factors, see the tadalafil price guide. Get a current quote for the actual prescribed product directly from a licensed pharmacy rather than using price comparisons to choose a dose.
The dispensing label should clearly identify tadalafil, the prescribed strength, the schedule, and any additional clinician instructions. A patient should ask for clarification if the label appears inconsistent with a previous prescription, if the intended daily versus as-needed use is unclear, or if a generic substitution is unfamiliar.
A pharmacist can verify product identity and explain dispensing details, while the prescriber owns clinical changes. For lawful dispensing procedures, visit the tadalafil prescription-pharmacy guide. A U.S. medication page cannot substitute for individualized prescribing.
A lack of benefit may reflect diagnosis, timing, sexual stimulation, other health conditions or a treatment plan that needs review. The response should not be to double a dose, add a second PDE5 inhibitor, or copy a regimen from a different patient. New cardiac symptoms or changes to other medications can also alter the risk-benefit balance.
Questions about onset belong in how quickly tadalafil may work; questions about the response window belong in how long tadalafil may last. Keeping these questions separate helps the clinician address the actual concern.
The U.S. label describes 10 mg as a usual starting dose in most patients, with clinician-directed adjustment according to response and tolerability. It is not a personal prescription.
The labeled ED once-daily regimen begins at 2.5 mg and may be adjusted to 5 mg by a prescriber. The schedule is different from as-needed use.
The routine lower-strength daily regimen and the as-needed regimen are different. Do not use a 20 mg tablet daily unless a prescriber has specifically assessed and directed your treatment.
Not necessarily. The usual BPH/ED+BPH framework is 5 mg once daily, but the U.S. label includes a 2.5 mg starting exception in certain renal impairment and a separate limited-duration context when used with finasteride. It is distinct from routine as-needed ED use.
No. Do not repeat doses to chase an immediate response. Review the prescribed schedule and discuss concerns with your clinician.
Yes. The Cialis label gives distinct renal-function limits for as-needed and once-daily regimens. For example, daily BPH/ED+BPH treatment can have a 2.5 mg starting exception when creatinine clearance is 30–50 mL/min. A clinician must use the actual renal assessment to decide suitability.
Do not combine different PDE5 inhibitors on your own. Combining ED medicines can increase risks and requires clinical oversight.
Ask the pharmacist or prescriber to clarify before taking it. The ingredient and milligram strength alone do not establish the correct frequency.